Upfront modified FOLFOXIRI plus panitumumab improves OS in RAS/BRAF wild-type mCRC
Upfront modified FOLFOXIRI plus panitumumab improves OS in RAS/BRAF wild-type mCRC
Primary cytoreductive surgery shows PFS benefit in advanced ovarian cancer
New MOAs in prostate cancer treatment - what’s next?
Molecular assay may help identify NSCLC patients who could benefit from adjuvant chemotherapy
Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced breast cancers
Neoadjuvant gemcitabine and cisplatin improves OS in resectable biliary tract cancer
Trastuzumab deruxtecan benefit for some advanced gastric cancers
HER2-positive breast cancer: Predicting pCR from clinicopathologic variables and genomic testing
Tumor Treating Fields plus chemo shows OS benefit in unresectable pancreatic cancer
ASCO 2025: Latest in EGFR positive NSCLC
Perioperative durvalumab and FLOT chemo can reduce risk of recurrence for some gastric cancers
BCG combined with mitomycin offers improved adjuvant treatment regimen for high-risk NMIBC